A Phase 3 interventional study of Ribavirin and Telaprevir in Genotype 1 Chronic Hepatitis C and Treatment Naive, sponsored by Janssen Infectious Diseases BVBA. Completed at 102 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-04.
Sponsored by Janssen Infectious Diseases BVBA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 8th largest by enrollment, is one of 7 that started in 2010, is one of 56 in phase 3, and was the 81st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 744 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Janssen Infectious Diseases BVBA is the lead sponsor of 14 studies on the registry; none are open to participants now.
Janssen Infectious Diseases BVBA has 5 studies filed under Hepatitis C — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.
This is a randomized (study drug assigned by chance), open-label (all persons know the study drug assignment) multicenter study to evaluate the effectiveness of telaprevir administered orally as 1125 milligram (mg) twice daily versus 750mg every 8 hours in combination with Peg-IFN-alfa-2a, administered via intramuscular injection once a week, and ribavirin, administered as an oral tablet twice a day, in treatment-naïve study participants with chronic hepatitis C virus (HCV) genotype 1 infection.
Telaprevir will be given orally (by mouth) from Day 1 through Week 12 as 3 tablets (1125mg) twice daily or 2 tablets (750mg) every 8 hours. Peg-IFN-alfa-2a will be administered once a week as an injection under the skin (180 microgram/week) from Day 1 through Week 24 or 48 (based on the patient's treatment response on week 4). Ribavirin is administered orally (by mouth) twice daily from Day 1 through Week 24 or 48 (based on the participant's treatment response on week 4) as 1,000-1,200 mg per day. After the end of treatment (Week 24, Week 48, or at early discontinuation of all study drugs), participants with undetectable HCV RNA at end of treatment will be required to attend follow-up visits until Week 72 safety/tolerability assessments will be performed throughout the treatment period and during the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
Drug: Ribavirin · Drug: Pegylated interferon alfa-2a · Drug: Telaprevir
Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated interferon alfa-2a
Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
750 mg (2 oral tablets) every 8 hours for 12 weeks
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)
The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned). SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).
Time frame: End of trial, 12 weeks after last planned dose
Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)
The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication. SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL). The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time. Consequently, by definition of SVR12, they were counted as not having achieved SVR12.
Time frame: End of trial, 24 weeks after last planned dose
Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)
The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned). SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).
Time frame: End of trial, 72 weeks after the start of study medication
Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.
The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.
Time frame: Baseline, Week 4 and Week 4+12.
Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs
The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 \>1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.
Time frame: Week 4, 12, 24, 32, 40
Percentage of Participants Who Relapsed During Follow-up Period
The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] during the 12-week follow-up period after previous HCV RNA \<25 IU/mL, target not detected, at end of treatment).
Time frame: During Follow-Up (24 weeks after the last dose of study drug)
Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)
The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.
Time frame: End of trial, 12 weeks after the last planned dose
This study evaluated the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with pegylated interferon and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.
| Milestone | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Started | 371 | 369 |
| Completed | 337 | 329 |
| Not completed | 34 | 40 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 18 | 22 |
| Withdrew: Withdrawal by subject | 13 | 13 |
| Withdrew: Switch to commercially available medicat | 1 | 4 |
| Withdrew: Other | 1 | 1 |
The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned). SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).
| percentage of participants with response | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned) | 72.8 | 74.3 |
The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication. SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL). The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time. Consequently, by definition of SVR12, they were counted as not having achieved SVR12.
| percentage of participants with response | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned) | 72.8 | 74.8 |
The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned). SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).
| percentage of participants with response | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned) | 69.0 | 70.2 |
The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.
| percentage of participants with response | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Baseline | 0 | 0 |
| at Week 4 | 67.4 | 69.4 |
| at Week 4 and Week 12 | 63.1 | 66.1 |
The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 \>1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.
| percentage of participants | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs | 9.7 | 10.3 |
The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] during the 12-week follow-up period after previous HCV RNA \<25 IU/mL, target not detected, at end of treatment).
| percentage of participants | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| Percentage of Participants Who Relapsed During Follow-up Period | 7.2 | 7.7 |
The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.
| percentage of participants with response | T12(q8h)/PR | T12(b.i.d.)/PR |
|---|---|---|
| CC genotype (n = 108; n = 103) | 86.8 | 92.4 |
| CT genotype (n = 207; n = 207) | 67.8 | 67.5 |
| TT genotype (n = 56; n = 59) | 64.9 | 65.5 |
Collected over Adverse event data were collected for the duration of study (12 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T12(q8h)/PR | — | 35/371 (9.4%) | 359/371 (96.8%) |
| T12(b.i.d.)/PR | — | 28/369 (7.6%) | 358/369 (97%) |
| Total | — | 63/740 (8.5%) | 717/740 (96.9%) |
| Event | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 14/371 | 13/369 | 27/740 |
| SyncopeNervous system disorders | 3/371 | 2/369 | 5/740 |
| RashSkin and subcutaneous tissue disorders | 1/371 | 2/369 | 3/740 |
| VertigoEar and labyrinth disorders | 0/371 | 2/369 | 2/740 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/371 | 0/369 | 2/740 |
| DehydrationMetabolism and nutrition disorders | 2/371 | 0/369 | 2/740 |
| PancytopeniaBlood and lymphatic system disorders | 1/371 | 1/369 | 2/740 |
| Urinary tract infectionInfections and infestations | 1/371 | 1/369 | 2/740 |
| PneumoniaInfections and infestations | 0/371 | 1/369 | 1/740 |
| AstheniaGeneral disorders | 1/371 | 1/369 | 2/740 |
| Event | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| FatigueGeneral disorders | 178/371 | 173/369 | 351/740 |
| PruritusSkin and subcutaneous tissue disorders | 158/371 | 158/369 | 316/740 |
| AnaemiaBlood and lymphatic system disorders | 148/371 | 155/369 | 303/740 |
| NauseaGastrointestinal disorders | 143/371 | 129/369 | 272/740 |
| RashSkin and subcutaneous tissue disorders | 133/371 | 129/369 | 262/740 |
| HeadacheNervous system disorders | 108/371 | 87/369 | 195/740 |
| PyrexiaGeneral disorders | 78/371 | 62/369 | 140/740 |
| Influenza like illnessGeneral disorders | 60/371 | 75/369 | 135/740 |
| AstheniaGeneral disorders | 72/371 | 65/369 | 137/740 |
| DiarrhoeaGastrointestinal disorders | 71/371 | 49/369 | 120/740 |
| Age, Categorical(Participants) | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| <=18 years | 3 | 0 | 3 |
| Between 18 and 65 years | 351 | 362 | 713 |
| >=65 years | 17 | 7 | 24 |
| Age, Continuous(years) | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| Mean | 48 (18 to 70) | 47.5 (19 to 70) | 47.7 (18 to 70) |
| Sex: Female, Male(Participants) | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| Female | 136 | 160 | 296 |
| Male | 235 | 209 | 444 |
| Region of Enrollment(participants) | T12(q8h)/PR | T12(b.i.d.)/PR | Total |
|---|---|---|---|
| Europe | 192 | 179 | 371 |
| North-America | 126 | 137 | 263 |
| Australia | 28 | 28 | 56 |
| Mexico | 5 | 4 | 9 |
| Brazil | 20 | 21 | 41 |
Showing the first 100 of 102 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2010, a primary completion of Aug 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ribavirin · Telaprevir · Peginterferon alfa-2a
Janssen Infectious Diseases BVBA